R.c. “merc” Mercure Jr.

Biography

Dr. Mercure has 57 years experience in high-technology management and investing and currently serves on the Boards of three public companies listed on the NYSE as well as a number of private companies. Most recently he co-founded CDM Optics, which was acquired by OmniVision Technologies (Nasdaq: OVTI). Prior to that, Dr. Mecure co-founded Ball Brothers Research Corporation, which is now Ball Aerospace Colorado. After retiring from Ball Brothers Research Corp., Dr. Mercure founded Colorado Venture Management. Dr. Mecure also serves as a Director of a number of non-profit entities including the Boulder Innovation Center, eSpace, and the University License Equity Holding, Inc.; serves as President of the University Corporation for Atmospheric Research Foundation; is Managing Director, Optoelectronic Computing Systems Center at the National Science Foundation Engineering Research Center; sits on the Technology Transfer Advisory Board of the Colorado School of Mines, and is a member of the External Advisory Board and the Engineering Advisory Board at the University of Colorado at Boulder, College of Engineering and Applied Sciences. Dr. Mecure holds a Ph.D. in Physics from the University of Colorado.  

Research Interest

AmideBio is a preclinical stage biotech company pursuing a series of therapeutic targets and diagnostic in the diabetes space. These include ultrastable insulin, glucose sensing insulin, solution stable glucagon and improved diagnostics for juvenile (T1) diabetes. In the diabetes space, a library of single chain insulin (SCI) analogs have been manufactured using a proprietary design protocol optimized for the production of SCI analogs that are resistant to thermal and chemical degradation at elevated temperature while maintaining maximal bioactivity